Literature DB >> 28571815

Hypothesis: Co-transfer of genuine embryos and implantation-promoting compounds via artificial containers improve endometrium receptivity.

Onder Celik1, Mustafa Acet2, Sudenaz Celik3, Levent Sahin4, Onder Koc5, Nilufer Celik6.   

Abstract

As with other organs endometrial functions are altered with the advancing age. Age related decrease in reproductive functions leads to decline in the number of oocytes retrieved and the synthesis of endometrial receptivity molecules. Despite the significant improvement in assisted reproductive technologies we do not have so many options to enhance endometrial receptivity. Due to lack of drugs having endometrium receptivity enhancement properties, oocyte donation seems to be the only solution for women with implantation failure. The euploid oocytes come from young and healthy donors may overcome age associated endometrial receptivity defect. Nevertheless, many reasons restrict us from using oocyte donation in women with implantation failure. We, therefore, hypothesized that by mimicking a young blastocyst's effect on endometrium, the transfer of genuine embryos and implantation-promoting compounds together might be the new treatment option for infertile women with recurrent implantation failure. Artificial beads, MI or GV oocytes, and empty zona can be used as a container for intrauterine replacement of implantation-promoting compounds.
Copyright © 2017 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Artificial blastocyst; Endometrium triggering; Implantation failure

Mesh:

Year:  2017        PMID: 28571815     DOI: 10.1016/j.mehy.2017.04.007

Source DB:  PubMed          Journal:  Med Hypotheses        ISSN: 0306-9877            Impact factor:   1.538


  1 in total

1.  Navigation problems of ICSI or naive blastocyst can be solved with artificial blastocyst.

Authors:  Onder Celik; Mustafa Acet; Haldun Arpaci; Levent Dikbas; Aytac Imren; Bulent Duran; Nilufer Celik; Sudenaz Celik; Cihat Unlu; Ibrahim Sahin; Suleyman Aydin
Journal:  Reprod Biol Endocrinol       Date:  2018-01-30       Impact factor: 5.211

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.